{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumors%2C+Non-small+Cell+Lung+Cancer", "query": { "condition": "Advanced Solid Tumors, Non-small Cell Lung Cancer" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 636, "total_pages": 64, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumors%2C+Non-small+Cell+Lung+Cancer&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-01T01:45:09.973Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06953089", "title": "DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "DB-1311/BNT324", "type": "DRUG" }, { "name": "BNT327", "type": "DRUG" }, { "name": "DB-1305/BNT325", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "DualityBio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 450, "start_date": "2025-07-18", "completion_date": "2030-06-30", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-01T01:45:09.973Z", "location_count": 15, "location_summary": "Los Angeles, California • Wheat Ridge, Colorado • Florida City, Florida + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Wheat Ridge", "state": "Colorado" }, { "city": "Florida City", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06953089" }, { "nct_id": "NCT05737706", "title": "Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Advanced Solid Tumor", "Non-small Cell Lung Cancer", "Colo-rectal Cancer", "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "MRTX1133", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirati Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2023-03-06", "completion_date": "2025-03-10", "has_results": false, "last_update_posted_date": "2025-04-06", "last_synced_at": "2026-10-01T01:45:09.973Z", "location_count": 14, "location_summary": "Phoenix, Arizona • New Haven, Connecticut • Lady Lake, Florida + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Lady Lake", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05737706" }, { "nct_id": "NCT03989115", "title": "Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "RMC-4630", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Drug: Osimertinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revolution Medicines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 113, "start_date": "2019-07-02", "completion_date": "2022-02-08", "has_results": true, "last_update_posted_date": "2023-06-26", "last_synced_at": "2026-10-01T01:45:09.973Z", "location_count": 21, "location_summary": "Scottsdale, Arizona • Duarte, California • Orange, California + 18 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03989115" }, { "nct_id": "NCT01999738", "title": "Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Non Small Cell Lung Carcinoma" ], "interventions": [ { "name": "EC1456 and EC20", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Endocyte", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 93, "start_date": "2013-10", "completion_date": "2018-04-26", "has_results": false, "last_update_posted_date": "2019-02-07", "last_synced_at": "2026-10-01T01:45:09.973Z", "location_count": 16, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 12 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01999738" }, { "nct_id": "NCT04190628", "title": "Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "BRAF V600 Mutation" ], "interventions": [ { "name": "ABM-1310", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ABM Therapeutics Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2020-06-16", "completion_date": "2024-04-05", "has_results": false, "last_update_posted_date": "2024-05-21", "last_synced_at": "2026-10-01T01:45:09.973Z", "location_count": 8, "location_summary": "San Francisco, California • Stanford, California • Miami, Florida + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04190628" }, { "nct_id": "NCT01976741", "title": "Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Rogaratinib (BAY1163877) oral solution", "type": "DRUG" }, { "name": "Rogaratinib (BAY1163877) oral tablet", "type": "DRUG" }, { "name": "Rogaratinib (BAY1163877) 800 mg BID", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 168, "start_date": "2013-12-30", "completion_date": "2020-01-09", "has_results": true, "last_update_posted_date": "2021-05-06", "last_synced_at": "2026-10-01T01:45:09.973Z", "location_count": 3, "location_summary": "Chicago, Illinois • Pittsburgh, Pennsylvania", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01976741" }, { "nct_id": "NCT03234712", "title": "A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors Cancer" ], "interventions": [ { "name": "ABBV-321", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2017-10-10", "completion_date": "2021-04-14", "has_results": false, "last_update_posted_date": "2021-05-06", "last_synced_at": "2026-10-01T01:45:09.973Z", "location_count": 14, "location_summary": "Springdale, Arkansas • Los Angeles, California • Sacramento, California + 10 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03234712" }, { "nct_id": "NCT00528619", "title": "A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Sunitinib, Pemetrexed, Cisplatin, Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 96, "start_date": "2006-11", "completion_date": "2010-04", "has_results": false, "last_update_posted_date": "2011-04-08", "last_synced_at": "2026-10-01T01:45:09.973Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00528619" }, { "nct_id": "NCT04956640", "title": "Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Colorectal Neoplasms", "Endometrial Neoplasms", "Ovarian Neoplasms", "Pancreatic Neoplasms", "Biliary Tract Neoplasms" ], "interventions": [ { "name": "LY3537982", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 540, "start_date": "2021-07-19", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-10-01T01:45:09.973Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04956640" }, { "nct_id": "NCT06792552", "title": "A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Platinum Resistant Ovarian Cancer", "Fallopian Tube Cancer", "Renal Cell Carcinoma (RCC)", "Papillary Renal Cell Carcinoma (Prcc)", "Uterine Serous Carcinoma (USC)", "NSCLC (Non-small Cell Lung Cancer)", "Primary Peritoneal Cancer" ], "interventions": [ { "name": "SIM0505 for injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NextCure, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 738, "start_date": "2025-02-26", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-10-01T01:45:09.973Z", "location_count": 9, "location_summary": "Orlando, Florida • Atlanta, Georgia • New Orleans, Louisiana + 6 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06792552" } ] }